Absci is trading at $10.47, up 10.81% in pre-market, with broader biotech strength the likeliest context, not a confirmed direct cause.
- No clear overnight company-specific catalyst has been identified. Absci announced routine participation in three investor conferences on October 27; that announcement does not establish a reason for the move.
- Reports describe the prior session’s advance as high-volume. The company’s next results are scheduled for November 12.